A股首份年报：沃华医药去年净利增超160%，终止4连降

Core Viewpoint - Wohuah Pharmaceutical has reported a significant turnaround in its financial performance for the year 2025, with notable increases in revenue and net profit compared to previous years [1][3]. Financial Performance - In 2025, Wohuah Pharmaceutical achieved an operating revenue of 816.95 million yuan, representing a year-on-year growth of 6.96% [2]. - The net profit attributable to shareholders reached 95.72 million yuan, marking a substantial increase of 162.93% from the previous year [2]. - Basic earnings per share were reported at 0.17 yuan, an increase of 183.33% compared to 0.06 yuan in 2024 [2]. Cash Flow and Assets - The net cash flow from operating activities was 128.53 million yuan, up 40.45% from 91.51 million yuan in 2024 [2]. - Total assets at the end of 2025 were 977.37 million yuan, a slight decrease of 0.85% from 985.73 million yuan in 2024 [2]. - The net assets attributable to shareholders increased by 3.79% to 723.82 million yuan compared to 697.37 million yuan in 2024 [2]. Product Performance - The cardiovascular system drugs generated revenue of 56.90 million yuan, a growth of 12.31% [2]. - Revenue from musculoskeletal system drugs decreased by 2.03% to 18.30 million yuan [2]. - Antiviral respiratory system drugs saw an increase in revenue to 26.09 million yuan, up 18.46% [2]. Dividend Distribution - The company plans to distribute a cash dividend of 1.46 yuan per 10 shares, totaling 84.27 million yuan, based on a total share capital of 577 million shares as of December 31, 2025 [3]. Market Reaction - On January 19, the stock price of Wohuah Pharmaceutical rose by 2.27%, closing at 7.66 yuan per share, with an intraday high of 7.78 yuan, the highest since January 2022 [4].